Business Context and Reporting Period
This Form 8-K was filed by Axsome Therapeutics, Inc. on September 18, 2017. The company is an emerging growth company incorporated in Delaware. The filing serves as a current report to announce upcoming corporate presentations by the Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely announces scheduled public presentations.
Guidance, Outlook, and Management Commentary
Herriot Tabuteau, M.D., the Chief Executive Officer, is scheduled to present at two industry conferences:
- Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017.
- The Cantor Fitzgerald Global Healthcare Conference on September 27, 2017.
The presentations will provide an overview of the Company's business and its late-stage clinical product candidates: AXS-02, AXS-05, and AXS-06. An updated presentation slide deck is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the content of the presentation slide deck attached as Exhibit 99.1 for specific clinical data on AXS-02, AXS-05, and AXS-06.
- Confirm the dates and times of the presentations at the Ladenburg Thalmann and Cantor Fitzgerald conferences.
- Review subsequent filings for any financial updates or clinical trial results discussed during these events.